Tauopathy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Tauopathy refers to a class of neurodegenerative disorders characterized by the abnormal accumulation of hyperphosphorylated tau protein within neurons and glia. These pathological tau aggregates form neurofibrillary tangles (NFTs), which disrupt cellular function, impair axonal transport, and ultimately lead to neuronal death. Tauopathies encompass a diverse group of diseases, including Alzheimer's Disease, Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Frontotemporal Dementia with parkinsonism linked to chromosome 17 (FTDP-17).1
The tau protein is encoded by the MAPT (Microtubule-Associated Protein Tau) gene located on chromosome 17q21.31. Under normal conditions, tau promotes microtubule assembly and stability, supporting intracellular transport. In tauopathy, post-translational modifications—particularly hyperphosphorylation—cause tau to detach from microtubules, aggregate into oligomers, and eventually form insoluble fibrils that constitute NFTs.2
The tau protein exists in six isoforms in the human brain, generated by alternative splicing of the MAPT gene. These isoforms differ in the number of N-terminal inserts (0, 1, or 2) and the presence of three or four repeat domains in the microtubule-binding region. Tau's primary physiological function is to bind and stabilize microtubules, facilitating the transport of organelles, vesicles, and proteins along axons. This function is regulated by the degree of tau phosphorylation, with approximately 2-3 moles of phosphate per mole of tau under normal conditions.2
The transition from functional tau to pathological tau begins with abnormal phosphorylation. In tauopathy, tau phosphorylation increases to approximately 6-8 moles of phosphate per mole of tau, causing a conformational change that promotes aggregation. Key kinases implicated in tau hyperphosphorylation include:3
Hyperphosphorylated tau monomers assemble into oligomers, which serve as toxic intermediates, then further aggregate into paired helical filaments (PHFs) and straight filaments (SFs) that comprise NFTs. The fibrillar tau in different tauopathies exhibits distinct structural conformations, or strains, which may determine disease-specific clinical phenotypes.4
Recent cryo-electron microscopy studies have revealed the atomic structure of tau filaments in Alzheimer's Disease, showing the characteristic cross-β sheet architecture. Importantly, distinct filament morphologies characterize different tauopathies, providing a molecular basis for the heterogeneity of these disorders.4
A landmark discovery in tau biology is the observation that pathological tau can propagate between neurons in a prion-like manner. Tau seeds can be released extracellularly, taken up by neighboring neurons, and template the conversion of endogenous tau into pathological aggregates. This propagation follows neural circuits, explaining the characteristic spreading pattern of tau pathology observed in neuroimaging studies.5
Tauopathies are classified based on the isoform composition of the aggregated tau protein and the cell types affected.
Primary tauopathies are disorders in which tau pathology is the defining feature:
In secondary tauopathies, tau pathology occurs as a downstream consequence of another primary insult:
Hyperphosphorylated tau loses its affinity for microtubules, leading to microtubule destabilization and impaired axonal transport. This disruption compromises the delivery of essential components to synapses and the retrograde transport of signaling molecules, contributing to synaptic dysfunction.6
Tau accumulates in dendritic spines and synapses, where it disrupts synaptic plasticity, impairs long-term potentiation (LTP), and contributes to cognitive decline. Tau oligomers are particularly toxic to synaptic function and may represent the critical pathogenic species.7
Tau pathology is closely linked to mitochondrial abnormalities. Tau interacts with mitochondria, compromising their function and distribution within neurons. This mitochondrial dysfunction contributes to energy deficits, increased oxidative stress, and apoptosis.8
The accumulation of NFTs disrupts neuronal connectivity through:
Cerebrospinal fluid markers for tauopathy include:
Tau PET ligands enable in vivo visualization of tau pathology:
Recent advances in ultrasensitive assays have enabled tau detection in blood:
Multiple therapeutic strategies are under development:
The study of Tauopathy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Arendt T, et al. "Tauopathies." Nat Rev Dis Primers 2018;4:13. DOI:10.1038/s41572-018-0029-0
Mandelkow E, Mandelkow E. "Tau in physiology and pathology." Nat Rev Neurosci 2012;13:51-62. DOI:10.1038/nrn3206
Gong CX, et al. "Post-translational modifications of tau protein in Alzheimer's Disease." J Alzheimers Dis 2020;77:939-954. DOI:10.3233/JAD-200692
Fitzpatrick AWP, et al. "Cryo-EM structures of tau filaments from Alzheimer's Disease." Nature 2017;547:185-190. DOI:10.1038/nature23002
Jucker M, Walker LC. "Propagation and spread of pathogenic protein aggregates in neurodegenerative diseases." Nat Neurosci 2013;16:1511-1522. DOI:10.1038/nn.3600
Mandelkow E, et al. "MARK kinases and tau phosphorylation." FEBS Lett 2003;537:21-28. DOI:10.1016/s0014-5793(03)00058-7
Ittner LM, et al. "Dendritic function of tau in Alzheimer's Disease." Cell 2010;141:1068-1083. DOI:10.1016/j.cell.2010.04.028
Rhoads JA, et al. "Tau and mitochondria in neurodegenerative disease." Int J Mol Sci 2021;22:7285. DOI:10.3390/ijms22147285
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 8 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 75% |
Overall Confidence: 36%